Key Points
-
•
The risk for chronic GVHD increased with each increment in the grade of acute GVHD.
-
•
The preceding profiles of acute GVHD have the potential to help in predicting the future occurrence of chronic GVHD and its severity.
Visual Abstract
Abstract
Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14 618 and 6135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95% CI, 1.12-2.58; P = .025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.
Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is an intensive and curative treatment for various hematologic malignancies and hematopoietic dysfunctions. Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allo-HCT. In previous studies,1, 2, 3 the incidence of chronic GVHD has been reported to be 15% to 50%, and chronic GVHD has been shown to have a detrimental effect on the quality of life, functional status, and survival outcomes.4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Previous studies have reported that recipient age,14, 15, 16, 17, 18, 19, 20 donor age,15,16,19 peripheral blood grafts,14, 15, 16,18,20, 21, 22, 23, 24 unrelated donor,15,16 female donor–male recipient combination,14, 15, 16,25, 26, 27 HLA disparity,14,23 in vivo T-cell depletion,14,17,28 and posttransplantation cyclophosphamide (PTCy)29, 30, 31 were associated with the risk for chronic GVHD. Several studies have also reported that antecedent acute GVHD was an independent risk factor for chronic GVHD.14,16,17,20,22,23,32 For example, 1 of the largest studies conducted by the Seattle group that analyzed only patients who underwent myeloablative conditioning regimens showed that only grade 3 to 4 acute GVHD, but not mild acute GVHD, increased the subsequent risk for chronic GVHD. However, several characteristics of acute GVHD, including the severity and involvement of specific organs, could potentially affect the subsequent risk for chronic GVHD differently in modern GVHD prophylaxis.
In this nationwide, retrospective study, we examined the influence of acute GVHD on chronic GVHD according to the acute GVHD profile. An increased understanding of the association between clinical acute and chronic GVHD would contribute to elucidating the underlying pathophysiology of chronic GVHD and help to identify potential candidates for early intervention for chronic GVHD.
Patients and methods
Donor source and patient selection
Clinical data were provided by the Transplantation Registry Unified Management Program of the Japanese Society for Transplantation and Cellular Therapy (JSTCT) and the Japanese Data Center for Hematopoietic Cell Transplantation.33,34
This study included adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, malignant lymphoma, or multiple myeloma who underwent their first allo-HCT between 2010 and 2021.
This retrospective study was approved by the data management committee of the Transplantation Registry Unified Management Program and by the institutional review board of the Jichi Medical University Saitama Medical Center and was performed in accordance with the Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants.
Definitions
Acute GVHD and chronic GVHD were diagnosed and graded according to standard criteria.35,36 The severity of chronic GVHD was also evaluated based on the National Institutes of Health (NIH) criteria.37 The disease risk index and the hematopoietic cell transplantation–specific comorbidity index were classified according to previous reports.38,39 In terms of donor type, a related donor with 6 of 6 antigen matches for HLA-A, -B, and -DR was considered to be an HLA-matched related donor. A related donor with 1 antigen mismatch of HLA was considered to be a mismatched related donor, and a related donor with ≥2 antigen mismatches of HLA was a haploidentical donor. An unrelated donor with 8 of 8 allelic matches of HLA-A, -B, -C, and -DRB1 was classified as an HLA-matched unrelated donor, whereas all other voluntary donors were classified as an HLA-mismatched unrelated donor. Conditioning regimens were distinguished according to the criteria of the Center for International Blood and Marrow Transplant Research.40 In vivo T-cell depletion included the use of antithymocyte globulin and alemtuzumab.
Statistical analysis
The patients with complete information on all covariates were classified into the bone marrow and peripheral blood stem cell transplantation (BM/PB) cohort and the umbilical cord blood transplantation (UCB) cohort. Because UCB is not a common donor source outside of Japan,41 the UCB cohort was analyzed separately in the same manner as the BM/PB cohort as follows. The cumulative incidence of chronic GVHD that required systemic steroids was set as the primary end point to exclude mild cases that have minimal impact on survival and quality of life.5,7,42 Outcomes were assessed using a landmark point at day 100 after allo-HCT. Among the eligible patients (n = 27 610), 6857 cases with either mortality or disease progression before day 100 were excluded from the analysis. The previous occurrences of acute GVHD were classified based on the maximum GVHD grades and organ involvement by day 100. In all multivariate analyses, the cause-specific Cox proportional hazard regression model was used to evaluate the subsequent risk for chronic GVHD. In addition to acute GVHD profiles, the following covariates were adjusted for in the multivariate analyses: recipient’s age, sex mismatch, disease risk index, hematopoietic cell transplantation–specific comorbidity index, donor type, donor source, conditioning regimen, GVHD prophylaxis, and in vivo T-cell depletion. P values for each acute GVHD grade (grade 1 vs 2 and grade 2 vs 3-4) were adjusted using the Bonferroni method.
A 2-tailed P value <.05 was considered to be statistically significant. All analyses were performed using R, version 4.2.3 (The Foundation for Statistical Computing, Vienna, Austria) and EZR, which is a graphical user interface for R (https://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html, Jichi Medical University Saitama Medical Center, Saitama, Japan).43
Results
Patient characteristics
This study included 14 618 cases in the BM/PB cohort and 6135 cases in the UCB cohort (Table 1). The median age was 50 years (range, 16-80) in the BM/PB cohort and 55 years (range, 16-79) in the UCB cohort. A total of 1969 patients (13.5%) in the BM/PB cohort and 213 (3.5%) in the UCB cohort underwent in vivo T-cell depletion. Among the patients who underwent allo-HCT from haplo-identical donors (n = 1715), 1165 patients (67.9%) were treated with PTCy. The BM/PB cohort included 5750 cases (39.3%) of no acute GVHD, 3403 (23.3%) of grade 1, 3884 (24.6%) of grade 2, and 1581 (10.8%) of grade 3 to 4 acute GVHD, whereas the UCB cohort included 2229 (36.3%) cases of no acute GVHD, 1199 (19.5%) of grade 1, 1941 (31.6%) of grade 2, and 766 (12.5%) of grade 3 to 4 acute GVHD. The median duration of follow-up for survivors was 52.3 months (range, 3.4-152.8) in the BM/PB cohort and 46.0 months (range, 3.4-153.5) in the UCB cohort.
Table 1.
Patient characteristics
BM/PB (n = 14 618) | UCB (n = 6135) | BM/PB (n = 14 618) | UCB (n = 6135) | |||
---|---|---|---|---|---|---|
Age | ||||||
>55 y | 5 221 (35.7) | 2956 (48.2) | Donor type | MRD | 4 176 (28.6) | 0 (0.0) |
36-55 y | 6 336 (43.3) | 2235 (36.4) | MUD | 5 214 (35.7) | 0 (0.0) | |
16-35 y | 3 061 (20.9) | 944 (15.4) | MMUD | 3 046 (20.8) | 0 (0.0) | |
Sex mismatch | ||||||
FtoM | 2 994 (20.5) | 1749 (28.5) | 1 locus MMRD | 467 (3.2) | 0 (0.0) | |
Others | 11 624 (79.5) | 4386 (71.5) | Haploidentical | 1 715 (11.7) | 0 (0.0) | |
Disease | ||||||
AML | 6 041 (41.3) | 3036 (49.5) | UCB | 0 (0.0) | 6135 (100.0) | |
ALL | 2 949 (20.2) | 1033 (16.8) | Donor source | BM | 8 818 (60.3) | 0 (0.0) |
MDS | 2 284 (15.6) | 830 (13.5) | PB | 5 800 (39.7) | 0 (0.0) | |
MPN | 871 (6.0) | 231 (3.8) | UCB | 0 (0.0) | 6135 (100.0) | |
ML | 2 372 (16.2) | 975 (15.9) | Conditioning | MAC | 9 592 (65.6) | 3776 (61.5) |
MM | 101 (0.7) | 30 (0.5) | RIC | 5 026 (34.4) | 2359 (38.5) | |
Disease risk index | ||||||
Low | 1 104 (7.6) | 345 (5.6) | GVHD prophylaxis | CsA based | 4 000 (27.4) | 1192 (19.4) |
Intermediate | 88 00 (60.2) | 3030 (49.4) | TAC based | 10 618 (72.6) | 4943 (80.6) | |
High | 3 789 (25.9) | 2190 (35.7) | In vivo T-cell depletion | 1 969 (13.5) | 213 (3.5) | |
Very high | 761 (5.2) | 526 (8.6) | SCT year | 2010-2015 | 7 056 (48.3) | 2261 (36.9) |
HCT-CI | ||||||
0-1 | 11 235 (76.9) | 4430 (72.2) | 2016-2021 | 7 562 (51.7) | 3874 (63.1) | |
≥2 | 3 312 (22.7) | 1659 (27.0) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CsA, cyclosporin; FtoM, female-to-male; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; ML, malignant lymphoma; MM, multiple myeloma; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; 1-locus MMRD, 1-locus mismatched related donor; RIC, reduced intensity conditioning; SCT, stem cell transplantation; TAC, tacrolimus.
Risk factors for chronic GVHD that require systemic steroids
The 4-year cumulative incidence of chronic GVHD that requires systemic steroids in the BM/PB cohort was 18.4% for grade 0, 23.1% for grade 1, 30.7% for grade 2, and 28.0% for grade 3 to 4 acute GVHD (Figure 1A), whereas the 4-year cumulative incidence in the UCB cohort was 8.0% for grade 0, 10.6% for grade 1, 17.9% for grade 2, and 18.3% for grade 3 to 4 acute GVHD (Figure 1B).
Figure 1.
Cumulative incidence of chronic GVHD requiring systemic steroids. (A) BM/PB cohort. (B) UCB cohort. The plots show the results using Gray’s test.
In the multivariate analyses that did not include acute GVHD as a covariate in the BM/PB cohort, younger age, female-to-male sex mismatch, donor type, PB, and the use of in vivo T-cell depletion were associated with the risk for chronic GVHD (Table 2). After adjusting for the baseline characteristics, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P < .001]; grade 1 vs 2 [HR, 1.41; 95% CI, 1.28-1.56; P < .001]), but the risk was similar between grade 2 and grade 3 to 4 acute GVHD (HR, 1.02; 95% CI, 0.91-1.15; P = 1.0; Table 2; Figure 2A). The interaction between acute GVHD and donor source (BM vs PB) was not statistically significant (interaction P value = .054).
Table 2.
Multivariate analysis of chronic GVHD with systemic steroid therapy in the BM/PB cohort
Risk factors | Adjustment for acute GVHD |
|||
---|---|---|---|---|
No |
Yes |
|||
HR (95% CI) | P value | HR (95% CI) | P value | |
Acute GVHD | ||||
None | NA | NA | Reference | 1.0 |
Grade 1 | NA | NA | 1.32 (1.19-1.46) | <.001 |
Grade 2 | NA | NA | 1.86 (1.70-2.04) | <.001 |
Grade 3-4 | NA | NA | 1.90 (1.69-2.14) | <.001 |
Age | ||||
≤56 y | 1.06 (0.97-1.15) | .19 | 1.08 (0.99-1.18) | .074 |
36-55 y | Reference | 1.0 | Reference | 1.0 |
16-35 y | 0.78 (0.71-0.86) | <.001 | 0.78 (0.71-0.86) | <.001 |
Sex mismatch | ||||
Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
Female-to-male | 1.49 (1.37-1.61) | <.001 | 1.49 (1.38-1.62) | <.001 |
Disease risk index | ||||
Low | Reference | 1.0 | Reference | 1.0 |
Intermediate | 0.94 (0.82-1.08) | .37 | 0.95 (0.83-1.09) | .46 |
High | 1.03 (0.89-1.19) | .72 | 1.01 (0.88-1.17) | .89 |
Very high | 0.95 (0.77-1.17) | .62 | 0.91 (0.74-1.12) | .39 |
HCT-CI | ||||
0-1 | Reference | 1.0 | Reference | 1.0 |
≥2 | 1.00 (0.92-1.09) | .92 | 1.01 (0.93-1.1) | .81 |
Donor type | ||||
Matched related | Reference | 1.0 | Reference | 1.0 |
Matched unrelated | 0.96 (0.85-1.09) | .53 | 0.9 (0.79-1.02) | .10 |
Mismatched unrelated | 1.12 (0.98-1.29) | .097 | 1.01 (0.87-1.16) | .95 |
1-locus MMRD | 1.04 (0.84-1.28) | .73 | 0.95 (0.76-1.17) | .61 |
Haploidentical | 0.63 (0.54-0.73) | <.001 | 0.61 (0.52-0.71) | <.001 |
Donor source | ||||
BM | Reference | 1.0 | Reference | 1.0 |
PB | 1.26 (1.14-1.39) | <.001 | 1.25 (1.13-1.38) | <.001 |
Conditioning regimen | ||||
MAC | Reference | 1.0 | Reference | 1.0 |
RIC | 0.89 (0.82-0.97) | .0080 | 0.89 (0.82-0.97) | .0095 |
GVHD prophylaxis | ||||
CsA based | Reference | 1.0 | Reference | 1.0 |
TAC based | 1.01 (0.91-1.12) | .82 | 1.06 (0.95-1.17) | .29 |
In vivo T-cell depletion | ||||
No | Reference | 1.0 | Reference | 1.0 |
Yes | 0.71 (0.63-0.80) | <.001 | 0.72 (0.64-0.81) | <.001 |
Abbreviations are explained in Table 1.
NA, Not available.
Figure 2.
Associations between acute and each subtype of chronic GVHD. (A) Chronic GVHD requiring systemic steroids in the BM/PB cohort. (B) Chronic GVHD requiring systemic steroids in the UCB cohort. (C) Lung chronic GVHD. (D) Extensive skin chronic GVHD. (E) NIH criteria–based moderate or severe chronic GVHD in the BM/PB cohort. (F) NIH criteria–based severe chronic GVHD in the BM/PB cohort. Ref, reference.
Similarly, in the UCB cohort, the subsequent risk for chronic GVHD that requires systemic steroids significantly increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [HR, 1.38; 95% CI, 1.08-1.76; P = .0092]; grade 1 vs 2 [HR, 1.73; 95% CI, 1.39-2.15; P < .001]), but this trend was not observed when grade 2 acute GVHD was compared with grade 3 to 4 acute GVHD (HR, 1.14; 95% CI, 0.92-1.40; P = .460; Table 3; Figure 2B).
Table 3.
Multivariate analysis of chronic GVHD with systemic steroid therapy in the UCB cohort
Risk factors | Adjustment for acute GVHD |
|||
---|---|---|---|---|
No |
Yes |
|||
HR (95% CI) | P value | HR (95% CI) | P value | |
Acute GVHD | ||||
None | NA | NA | Reference | 1.0 |
Grade 1 | NA | NA | 1.38 (1.08-1.76) | .0092 |
Grade 2 | NA | NA | 2.38 (1.97-2.88) | <.001 |
Grade 3-4 | NA | NA | 2.71 (2.14-3.41) | <.001 |
Age | ||||
≤56 y | 1.09 (0.91-1.29) | .35 | 1.06 (0.90-1.27) | .48 |
36-55 y | Reference | 1.0 | Reference | 1.0 |
16-35 y | 0.89 (0.71-1.12) | .32 | 0.88 (0.70-1.11) | .29 |
Sex mismatch | ||||
Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
Female-to-male | 1.08 (0.92-1.27) | .36 | 1.12 (0.95-1.31) | .17 |
Disease risk index | ||||
Low | Reference | 1.0 | Reference | 1.0 |
Intermediate | 0.88 (0.64-1.19) | .40 | 0.91 (0.67-1.24) | .56 |
High | 0.81 (0.59-1.11) | .19 | 0.81 (0.59-1.11) | .19 |
Very high | 0.91 (0.62-1.33) | .62 | 0.93 (0.63-1.36) | .70 |
HCT-CI | ||||
0-1 | Reference | 1.0 | Reference | 1.0 |
≥2 | 1.00 (0.85-1.19) | .97 | 0.98 (0.82-1.16) | .78 |
Conditioning regimen | ||||
MAC | Reference | 1.0 | Reference | 1.0 |
RIC | 0.76 (0.65-0.90) | .0018 | 0.81 (0.69-0.96) | .016 |
GVHD prophylaxis | ||||
CsA based | Reference | 1.0 | Reference | 1.0 |
TAC based | 1.21 (0.99-1.48) | .065 | 1.25 (1.02-1.53) | .029 |
In vivo T-cell depletion | ||||
No | Reference | 1.0 | Reference | 1.0 |
Yes | 0.74 (0.47-1.18) | .21 | 0.74 (0.47-1.18) | .20 |
Abbreviations are explained in Table 1.
We also evaluated the how organ involvement during acute GVHD affected the risk for chronic GVHD that requires systemic steroids. Involvement of the skin, gastrointestinal system, and liver carried a similar risk for chronic GVHD in the BM/PB cohort (skin [HR, 1.28; 95% CI, 1.11-1.47; P < .001]; gut [HR, 1.24; 95% CI, 1.13-1.37; P <.001]; liver [HR, 1.24; 95% CI, 1.06-1.46; P = .0094]; supplemental Table 1). Moreover, the skin (HR, 1.61; 95% CI, 1.25-2.07; P < .001) and gut (HR, 1.26; 95% CI, 1.08-1.47; P = .003), but not the liver (HR, 0.93; 95% CI, 0.40-2.12; P = .863) during acute GVHD were associated with an increased risk for lung chronic GVHD. Involvement of any of these 3 organs during acute GVHD, particularly skin involvement, were also associated with the risk for extensive skin chronic GVHD44 (skin [HR, 1.90; 95% CI, 1.51-2.39; P < .001]; gut [HR, 1.18; 95% CI, 1.03-1.34; P = .017]; liver [HR, 1.43; 95% CI, 1.14-1.78; P = .0017]).
Association of the severity between acute and chronic GVHD
Associations between the severity of acute and chronic GVHD were examined only in the BM/PB cohort because of a limited number of events in the UCB cohort. Lung chronic GVHD, manifesting as bronchiolitis obliterans syndrome, is considered a high-risk manifestation that is associated with poor outcomes. We first evaluated the impact of the grade of acute GVHD on the risk for lung chronic GVHD. The 4-year cumulative incidence of lung chronic GVHD was 6.7% in grade 0, 8.8% in grade 1, 9.6% in grade 2, and 10.1% in grade 3 to 4 acute GVHD (Figure 3A). In a multivariate analysis, the eventual HR for the risk for lung chronic GVHD increased with each increase in the grade of acute GVHD (grade 1: HR, 1.34; grade 2: HR, 1.48; grade 3-4: HR, 1.72), but the differences among grade 1 to 4 were not statistically significant (grade 1 vs 2 [HR, 1.10; 95% CI, 0.94-1.29; P = .468]; grade 2 vs 3-4 [HR, 1.16; 95% CI, 0.96-1.41; P = .252]; Figure 2C; supplemental Table 2).
Figure 3.
Cumulative incidence of each subtype of chronic GVHD in the BM/PB cohort. (A) Lung chronic GVHD. (B) Extensive skin chronic GVHD. (C) NIH criteria–based moderate or severe chronic GVHD. (D) NIH criteria–based severe chronic GVHD. The plots show the results using Gray’s test.
Similarly, we evaluated the impact of acute GVHD on the risk for extensive skin chronic GVHD,44 because this is another phenotype that increases the risk for nonrelapse mortality (NRM).7,8 The 4-year cumulative incidence of extensive skin chronic GVHD is 7.5% in grade 0, 10.0% in grade 1, 15.0% in grade 2, and 14.3% in grade 3 to 4 acute GVHD (Figure 3B). The risk for extensive skin chronic GVHD was increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [HR, 1.34; 95% CI, 1.16-1.55; P < .001]; grade 1 vs 2 [HR, 1.57; 95% CI, 1.37-1.81; P < .001]), but the risk was equivalent between grade 2 and grade 3 to 4 acute GVHD (HR, 1.07; 95% CI, 0.91-1.25; P = 1.0; Figure 2D; supplemental Table 2).
We also evaluated the impact of the grade of acute GVHD on the severity of chronic GVHD assessed using the NIH criteria for the recent BM/PB cohort, included between 2019 and 2021, for which information on severity was available in our database. The 2-year cumulative incidence of moderate or severe chronic GVHD was 14.0% in grade 0, 13.5% in grade 1, 21.0% in grade 2, and 23.3% in grade 3 to 4 acute GVHD (Figure 3C). In a multivariate analysis, the risk for moderate or severe chronic GVHD significantly increased in patients with grade 2 (HR, 1.53; 95% CI, 1.25-1.88; P < .001) and those with grade 3 to 4 acute GVHD (HR, 1.94; 95% CI, 1.49-2.52; P < .001), but the difference between grade 2 and grade 3 to 4 was not statistically significant (HR, 1.26; 95% CI, 0.96-1.66; P = .179; Table 4; Figure 2E).
Table 4.
Multivariate analysis of chronic GVHD according to NIH criteria in the BM/PB cohort
Risk factors | Moderate/Severe |
Severe |
||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Acute GVHD | ||||
None | Reference | 1.0 | Reference | 1.0 |
Grade 1 | 0.93 (0.74-1.18) | .57 | 1.18 (0.80-1.72) | .41 |
Grade 2 | 1.53 (1.25-1.88) | <.001 | 1.55 (1.09-2.21) | .014 |
Grade 3-4 | 1.94 (1.49-2.53) | <.001 | 2.65 (1.76-3.98) | <.001 |
Age | ||||
≤56 y | 1.16 (0.95-1.42) | .14 | 1.25 (0.90-1.73) | .18 |
36-55 y | Reference | 1.0 | Reference | 1.0 |
16-35 y | 0.90 (0.70-1.15) | .40 | 1.06 (0.71-1.58) | .76 |
Sex mismatch | ||||
Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
Female-to-male | 1.14 (0.93-1.40) | .21 | 1.04 (0.73-1.47) | .83 |
Disease risk index | ||||
Low | Reference | 1.0 | Reference | 1.0 |
Intermediate | 0.87 (0.63-1.20) | .39 | 0.93 (0.54-1.58) | .78 |
High | 0.84 (0.59-1.18) | .31 | 0.93 (0.52-1.66) | .81 |
Very high | 0.68 (0.37-1.22) | .19 | 1.39 (0.62-3.11) | .43 |
HCT-CI | ||||
0-1 | Reference | 1.0 | Reference | 1.0 |
≥2 | 1.03 (0.85-1.25) | .77 | 1.06 (0.78-1.46) | .70 |
Donor type | ||||
Matched related | Reference | 1.0 | Reference | 1.0 |
Matched unrelated | 1.16 (0.87-1.55) | .31 | 1.77 (1.10-2.86) | .020 |
Mismatched unrelated | 1.19 (0.86-1.65) | .29 | 1.82 (1.06-3.13) | .031 |
1-locus MMRD | 0.74 (0.34-1.59) | .44 | 1.11 (0.34-3.66) | .86 |
Haploidentical | 0.63 (0.47-0.86) | .0038 | 0.75 (0.44-1.25) | .27 |
Donor source | ||||
BM | Reference | 1.0 | Reference | 1.0 |
PB | 1.33 (1.07-1.64) | .010 | 1.76 (1.24-2.50) | .0016 |
Conditioning regimen | ||||
MAC | Reference | 1.0 | Reference | 1.0 |
RIC | 0.91 (0.75-1.11) | .36 | 0.88 (0.64-1.22) | .45 |
GVHD prophylaxis | ||||
CsA based | Reference | 1.0 | Reference | 1.0 |
TAC based | 1.00 (0.77-1.29) | .97 | 0.99 (0.64-1.54) | .97 |
In vivo T-cell depletion | ||||
No | Reference | 1.0 | Reference | 1.0 |
Yes | 0.77 (0.6-0.99) | .039 | 0.41 (0.25-0.67) | <.001 |
Abbreviations are explained in Table 1.
The 2-year cumulative incidence of severe chronic GVHD was 4.7% in grade 0, 5.5% in grade 1, 7.1% in grade 2, and 10.3% in grade 3 to 4 acute GVHD (Figure 3D). A multivariate analysis showed that grade 2 to 4 acute GVHD was significantly associated with a higher risk for severe chronic GVHD (grade 2: HR, 1.55; 95% CI, 1.09-2.21; P = .014; grade 3-4: HR, 2.64; 95% CI, 1.76-3.98; P < .001; Table 4; Figure 2F). Remarkably, we detected a significant difference between grade 2 and grade 3 to 4 acute GVHD in terms of the risk for severe chronic GVHD (HR, 1.70; 95% CI, 1.12-2.58; P = .025).
Survival outcomes from the treatment initiation of chronic GVHD
We evaluated the impact of acute GVHD on NRM and overall survival (OS) only among patients in the BM/PB cohort with chronic GVHD that required systemic steroids. The cumulative incidence of NRM within 4 years was 22.8% in grade 0, 21.9% in grade 1, 24.1% in grade 2. and 41.1% in grade 3 to 4 acute GVHD (supplemental Figure A), whereas 4-year OS was 65.8% in grade 0, 67.0% in grade 1, 65.6% in grade 2, and 51.2% in grade 3 to 4 acute GVHD (supplemental Figure B). In the multivariate analysis, only grade 3 to 4 had an adverse impact on NRM (HR, 2.28; 95% CI, 1.86-2.79; P < .001) and OS (HR, 1.80; 95% CI, 1.51-2.16; P < .001; supplemental Table 3).
Discussion
This study elucidated the close association between acute and chronic GVHD. In this large Japanese cohort, baseline characteristics, including recipient's age, donor type, sex mismatch, PB, and the use of in vivo T-cell depletion, were associated with the risk for chronic GVHD that requires systemic steroids, which is consistent with previous studies.14, 15, 16,28 The risk for chronic GVHD that requires systemic steroids increased with each increase in GVHD grade among grade 0, 1, and 2 to 4 in the BM/PB cohort, and these findings were also confirmed in the UCB cohort. Moreover, we found that the risk for severe chronic GVHD, as assessed by the NIH criteria, was significantly higher among those with grade 3 to 4 acute GVHD, indicating a strong association between the severity of acute and chronic GVHD.
Severe chronic GVHD remains one of the most morbid complications after allo-HCT.1,8 Specifically, lung chronic GVHD, often referred to as bronchiolitis obliterans syndrome, is 1 of the most devastating subtypes of chronic GVHD.37 Although several treatment options have become available for chronic GVHD, long-term survival remains unsatisfactory.6, 7, 8,45,46 In particular, it is challenging to ameliorate organ dysfunction after the involved organs of chronic GVHD progress to fibrosis. Therefore, early interventions before progression to fibrosis are potential treatment strategies for chronic GVHD. Notably, the subsequent risk for severe chronic GVHD increased commensurately with the severity of acute GVHD, whereas the adjustment for the grade of acute GVHD showed no remarkable influence on other risk factors of chronic GVHD. Furthermore, we found that previous severe acute GVHD exhibited a notable adverse impact on survival outcomes among patients who developed chronic GVHD that required systemic steroids. This was not shown in the previous studies, which did not account for the severity of previous acute GVHD.47,48 Although a history of acute GVHD alone is not a sufficient trigger to initiate early interventions, the inclusion of a history of acute GVHD could enhance the predictive accuracy of models for chronic GVHD that include baseline characteristics (eg, PB or sex mismatch) and potential biomarkers.49 Therefore, these findings might help to identify potential candidates who could benefit from early treatment interventions.
Although the pathophysiological mechanism between acute and chronic GVHD has not been fully elucidated, thymus damage caused by acute GVHD might contribute to the development of chronic GVHD. Various studies using mouse models have suggested that damaged thymus caused by acute GVHD impairs negative selection, thereby inducing chronic GVHD.50, 51, 52, 53, 54 Although the thymus in human adults is gradually replaced by fat, rebound thymic hyperplasia is observed after chemotherapy until the patient is ∼35 years old.55 Furthermore, a recent retrospective study suggested that there is residual thymic function after thymus atrophy in older adults.56 Our study demonstrated a reduced risk for chronic GVHD in younger patients (<36 years) before complete thymus atrophy, indicating that the reserved functionality of the thymus in this population might help to avoid the development of chronic GVHD. These findings partially support the notion that impaired thymus function caused by acute GVHD may underlie the mechanism of chronic GVHD. One of the other potential explanations is the involvement of dysbiosis. One study suggested that dysbiosis is associated with the incidence of chronic GVHD.57 Dysbiosis caused by previous acute GVHD might induce subsequent chronic GVHD.58 Prolonged use of calcineurin inhibitors for acute GVHD might also inhibit immune tolerance and induce chronic GVHD.59,60 Although further investigations are required, our findings might serve as a basis for exploring the underlying pathophysiological mechanisms in acute and chronic GVHD.
This study had several limitations. First, some subgroup analyses, including the association between the severity of acute and chronic GVHD assessed by the NIH criteria in the UCB cohort, could not be performed because of the small sample size. Second, although several biomarkers have the potential to predict the future occurrence of chronic GVHD and its outcomes,61, 62, 63, 64, 65, 66, 67, 68 serum samples were not available in our database. Third, our registry lacked data on late acute GVHD, which is increasing according to the recent changes in practice.69 For instance, late acute GVHD can sometimes develop into chronic GVHD overlapped by acute GVHD (progressive onset). Our study could not include such scenarios in the analysis. Fourth, the study included a limited number of patients who received PTCy as GVHD prophylaxis, all of whom underwent allo-HCT from haplo-identical donors because the use of PTCy in nonhaplo-identical settings was not permitted in Japan during the study period.
In conclusion, grade 2 to 4 acute GVHD was significantly associated with an increased risk for chronic GVHD. In addition, our study suggested that the risk for severe chronic GVHD correlated with the severity of acute GVHD. Although our findings should be validated in other retrospective and prospective cohorts, the preceding profiles of acute GVHD have the potential to help in predicting the future occurrence of chronic GVHD and its severity, which could facilitate the development of treatment strategies for chronic GVHD.
Conflict-of-interest disclosure: M. Tamaki reports receiving honoraria from Astellas Pharma and Kyowa Kirin. Y. Kanda reports receiving honoraria from Pfizer, Sumitomo Pharma, Novartis Pharma, Sanofi K.K., Chugai Pharmaceutical, SymBio Pharmaceuticals, Bristol Myers Squibb, Janssen Pharmaceutical K.K., Asahi Kasei Pharma, MSD, Astellas Pharma, Kyowa Kirin; and subsidies from Sumitomo Pharma, Chugai Pharmaceutical, Kyowa Kirin, and Eisai. The remaining authors declare no competing financial interests.
Acknowledgments
The authors are grateful for the work of all of the physicians and data managers at the centers that contributed valuable data on transplantation to the JSTCT. The authors thank all of the members of the Transplant Registry Unified Management committees at JSTCT for their dedicated data management.
Authorship
Contribution: M. Tamaki and Y. Akahoshi contributed equally as primary investigators, and conceived the original idea, analyzed the data, and wrote the manuscript; K.M., Y.I., S.T., and J.K. advised on methods and wrote the manuscript; N.U., N.D., M. Tanaka, T.N., H.O., H.N., M.O., Y. Katayama, K.-i. M., and M.S. collected the data and revised the manuscript; F.I., Y. Kanda, and T.F. collected data, revised the manuscript, and were responsible for data management at JSTCT; Y. Atsuta managed the unified registry database and revised the manuscript; J.K. was responsible for this project of the JSTCT/GVHD Working Group; and all authors approved the final version of the manuscript.
Footnotes
M.T. and Y.A. contributed equally to this study.
The data of this study are not publicly available because of ethical restrictions that exceed the scope of the recipient/donor’s consent for research used in the registry.
The full-text version of this article contains a data supplement.
Contributor Information
Masaharu Tamaki, Email: m.tamaki.221@gmail.com.
Yu Akahoshi, Email: akahoshiu@gmail.com.
Supplementary Material
References
- 1.Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266–274. doi: 10.1016/j.bbmt.2014.10.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Boyiadzis M, Arora M, Klein JP, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015;21(9):2020–2028. doi: 10.1158/1078-0432.CCR-14-0586. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019;54(5):662–673. doi: 10.1038/s41409-018-0340-0. [DOI] [PubMed] [Google Scholar]
- 4.Yu J, Hamilton BK, Turnbull J, et al. Patient-reported symptom burden and impact on daily activities in chronic graft-versus-host disease. Cancer Med. 2023;12(3):3623–3633. doi: 10.1002/cam4.5209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651–4657. doi: 10.1182/blood-2010-11-319509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–615. doi: 10.1182/blood-2014-08-551994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Inamoto Y, Martin PJ, Storer BE, et al. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica. 2014;99(10):1618–1623. doi: 10.3324/haematol.2014.109611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.DeFilipp Z, Alousi AM, Pidala JA, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5(20):4278–4284. doi: 10.1182/bloodadvances.2021004941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Baumrin E, Baker LX, Byrne M, et al. Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease. JAMA Dermatol. 2023;159(4):393–402. doi: 10.1001/jamadermatol.2022.6624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Lee SJ, Onstad L, Chow EJ, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018;103(9):1535–1541. doi: 10.3324/haematol.2018.192930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kurosawa S, Yamaguchi T, Oshima K, et al. Resolved versus active chronic graft-versus-host disease: impact on post-transplantation quality of life. Biol Blood Marrow Transplant. 2019;25(9):1851–1858. doi: 10.1016/j.bbmt.2019.05.016. [DOI] [PubMed] [Google Scholar]
- 12.Lee CJ, Wang T, Chen K, et al. Severity of chronic graft-versus-host disease and late effects following allogeneic hematopoietic cell transplantation for adults with hematologic malignancy. Transplant Cell Ther. 2024;30(1):97.e1–97.e14. doi: 10.1016/j.jtct.2023.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lee CJ, Wang T, Chen K, et al. Association of chronic graft-versus-host disease with late effects following allogeneic hematopoietic cell transplantation for children with hematologic malignancy. Transplant Cell Ther. 2022;28(10):712.e1–712.e8. doi: 10.1016/j.jtct.2022.07.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kanda J, Nakasone H, Atsuta Y, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transplant. 2014;49(2):228–235. doi: 10.1038/bmt.2013.151. [DOI] [PubMed] [Google Scholar]
- 15.Watkins BK, Horan J, Storer B, Martin PJ, Carpenter PA, Flowers ME. Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant. Bone Marrow Transplant. 2017;52(4):625–626. doi: 10.1038/bmt.2016.328. [DOI] [PubMed] [Google Scholar]
- 16.Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–3219. doi: 10.1182/blood-2010-08-302109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Afram G, Simón JAP, Remberger M, et al. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Med Oncol. 2018;35(6):79. doi: 10.1007/s12032-018-1127-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lazaryan A, Weisdorf DJ, DeFor T, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 2016;22(1):134–140. doi: 10.1016/j.bbmt.2015.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Qayed M, Wang T, Hemmer MT, et al. Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: implications for prophylaxis. Biol Blood Marrow Transplant. 2018;24(3):521–528. doi: 10.1016/j.bbmt.2017.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Cuvelier GDE, Li A, Drissler S, et al. "Age related differences in the biology of chronic graft-versus-host disease after hematopoietic stem cell transplantation". Front Immunol. 2020;11 doi: 10.3389/fimmu.2020.571884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127(2):260–267. doi: 10.1182/blood-2015-08-663823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019;134(3):304–316. doi: 10.1182/blood.2019000216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant. 2016;22(10):1781–1791. doi: 10.1016/j.bbmt.2016.06.020. [DOI] [PubMed] [Google Scholar]
- 24.Im A, Rashidi A, Wang T, et al. Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2020;26(8):1459–1468. doi: 10.1016/j.bbmt.2020.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Bazarbachi A, Boumendil A, Finel H, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2020;188(5):745–756. doi: 10.1111/bjh.16182. [DOI] [PubMed] [Google Scholar]
- 26.Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22(8):755–761. doi: 10.1038/sj.bmt.1701423. [DOI] [PubMed] [Google Scholar]
- 27.Nakasone H, Tian L, Sahaf B, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood. 2015;125(20):3193–3201. doi: 10.1182/blood-2014-11-613323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Chang YJ, Wu DP, Lai YR, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020;38(29):3367–3376. doi: 10.1200/JCO.20.00150. [DOI] [PubMed] [Google Scholar]
- 29.Saliba RM, Alousi AM, Pidala J, et al. Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis. Transplant Cell Ther. 2022;28(10):681–693. doi: 10.1016/j.jtct.2022.07.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Bolaños-Meade J, Hamadani M, Wu J, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338–2348. doi: 10.1056/NEJMoa2215943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Mehta RS, Saliba RM, Rondon G, et al. Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation. Transplant Cell Ther. 2022;28(10):695.e1–695.e10. doi: 10.1016/j.jtct.2022.07.021. [DOI] [PubMed] [Google Scholar]
- 32.Chen YB, Wang T, Hemmer MT, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplant. 2017;52(3):400–408. doi: 10.1038/bmt.2016.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data) Int J Hematol. 2016;103(1):3–10. doi: 10.1007/s12185-015-1894-x. [DOI] [PubMed] [Google Scholar]
- 34.Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103(1):11–19. doi: 10.1007/s12185-015-1907-9. [DOI] [PubMed] [Google Scholar]
- 35.Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828. [PubMed] [Google Scholar]
- 36.Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11(12):945–956. doi: 10.1016/j.bbmt.2005.09.004. [DOI] [PubMed] [Google Scholar]
- 37.Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi: 10.1016/j.bbmt.2014.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671. doi: 10.1182/blood-2014-01-552984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. doi: 10.1182/blood-2005-05-2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2009;15(3):367–369. doi: 10.1016/j.bbmt.2008.12.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.D'Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177–e182. doi: 10.1016/j.bbmt.2020.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Im A, Pusic I, Onstad L, et al. Patient-reported treatment response in chronic graft-versus-host disease. Haematologica. 2024;109(1):143–150. doi: 10.3324/haematol.2023.282734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–217. doi: 10.1016/0002-9343(80)90380-0. [DOI] [PubMed] [Google Scholar]
- 45.Palmer J, Williams K, Inamoto Y, et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(3):337–344. doi: 10.1016/j.bbmt.2013.11.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Miklos DB, Abu Zaid M, Cooney JP, et al. Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study. J Clin Oncol. 2023;41(10):1876–1887. doi: 10.1200/JCO.22.00509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117(24):6714–6720. doi: 10.1182/blood-2010-12-323824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Arora M, Pidala J, Cutler CS, et al. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia. 2013;27(5):1196–1201. doi: 10.1038/leu.2012.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Martens MJ, Kou J, Logan BR, Paczesny S. Machine learning validates risk biomarkers of chronic graft-versus-host disease in 936 patients from BMT CTN 0201 & 1202 cohorts. Blood. 2023;142(suppl 1):479. [Google Scholar]
- 50.Zeiser R, Teshima T. Nonclassical manifestations of acute GVHD. Blood. 2021;138(22):2165–2172. doi: 10.1182/blood.2021012431. [DOI] [PubMed] [Google Scholar]
- 51.Hauri-Hohl MM, Keller MP, Gill J, et al. Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood. 2007;109(9):4080–4088. doi: 10.1182/blood-2006-07-034157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Krenger W, Rossi S, Piali L, Holländer GA. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood. 2000;96(1):347–354. [PubMed] [Google Scholar]
- 53.Dertschnig S, Hauri-Hohl MM, Vollmer M, Holländer GA, Krenger W. Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GVHD. Blood. 2015;125(17):2720–2723. doi: 10.1182/blood-2014-08-597245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007;109(4):1756–1764. doi: 10.1182/blood-2006-08-042853. [DOI] [PubMed] [Google Scholar]
- 55.Choyke PL, Zeman RK, Gootenberg JE, Greenberg JN, Hoffer F, Frank JA. Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. AJR Am J Roentgenol. 1987;149(2):269–272. doi: 10.2214/ajr.149.2.269. [DOI] [PubMed] [Google Scholar]
- 56.Kooshesh KA, Foy BH, Sykes DB, Gustafsson K, Scadden DT. Health consequences of thymus removal in adults. N Engl J Med. 2023;389(5):406–417. doi: 10.1056/NEJMoa2302892. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Markey KA, Schluter J, Gomes ALC, et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020;136(1):130–136. doi: 10.1182/blood.2019003369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Rafei H, Jenq RR. Microbiome-intestine cross talk during acute graft-versus-host disease. Blood. 2020;136(4):401–409. doi: 10.1182/blood.2019000950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Senjo H, Harada S, Kubota SI, et al. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood. 2023;142(5):477–492. doi: 10.1182/blood.2023019875. [DOI] [PubMed] [Google Scholar]
- 60.Wang Y, Ullah MA, Waltner OG, et al. Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD. J Clin Invest. 2024;134(11) doi: 10.1172/JCI170125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Subburaj D, Ng B, Kariminia A, et al. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. Blood. 2022;139(2):287–299. doi: 10.1182/blood.2021013244. [DOI] [PubMed] [Google Scholar]
- 62.Inamoto Y, Martin PJ, Onstad LE, et al. Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(9):759.e1–759.e8. doi: 10.1016/j.jtct.2021.06.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Reikvam H, Vo AK, Johansen S, et al. MicroRNA serum profiles and chronic graft-versus-host disease. Blood Adv. 2022;6(18):5295–5306. doi: 10.1182/bloodadvances.2021005930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Inamoto Y, Martin PJ, Lee SJ, et al. Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. Blood Adv. 2020;4(11):2409–2417. doi: 10.1182/bloodadvances.2020001485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Yu J, Storer BE, Kushekhar K, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34(22):2583–2590. doi: 10.1200/JCO.2015.65.9615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Inamoto Y, Martin PJ, Paczesny S, et al. Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(8):1250–1256. doi: 10.1016/j.bbmt.2017.04.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Akahoshi Y, Nakasone H, Kawamura K, et al. Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT. Blood Adv. 2019;3(21):3287–3296. doi: 10.1182/bloodadvances.2019000629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Paczesny S, Hakim FT, Pidala J, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015;21(5):780–792. doi: 10.1016/j.bbmt.2015.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Akahoshi Y, Spyrou N, Hogan WJ, et al. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Adv. 2023;7(16):4479–4491. doi: 10.1182/bloodadvances.2023009885. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.